We hypothesized that the vascular normalization period we observed with the anti-S1P mAb (optimal time of 5 to 9 days) offers an opportunity for enhanced response to docetaxel, the standard of care for the treatment of metastatic prostate cancer [61, 62]. This evidence concerns the gene MBTPS1 and metastatic prostate carcinoma.